These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33487120)

  • 1. Bispecific antibody target pair discovery by high-throughput phenotypic screening using in vitro combinatorial Fab libraries.
    Bhatta P; Whale KD; Sawtell AK; Thompson CL; Rapecki SE; Cook DA; Twomey BM; Mennecozzi M; Starkie LE; Barry EMC; Peters SJ; Kamal AM; Finney HM
    MAbs; 2021; 13(1):1859049. PubMed ID: 33487120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intein mediated high throughput screening for bispecific antibodies.
    Hofmann T; Schmidt J; Ciesielski E; Becker S; Rysiok T; Schütte M; Toleikis L; Kolmar H; Doerner A
    MAbs; 2020; 12(1):1731938. PubMed ID: 32151188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies.
    Dietrich S; Gross AW; Becker S; Hock B; Stadlmayr G; Rüker F; Wozniak-Knopp G
    Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140250. PubMed ID: 31295556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greatest Hits-Innovative Technologies for High Throughput Identification of Bispecific Antibodies.
    Hofmann T; Krah S; Sellmann C; Zielonka S; Doerner A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSMA-targeted bispecific Fab conjugates that engage T cells.
    Patterson JT; Isaacson J; Kerwin L; Atassi G; Duggal R; Bresson D; Zhu T; Zhou H; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5490-5495. PubMed ID: 29126850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
    Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
    J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bispecific antibody, S-Fab, induces potent cancer cell killing.
    Li L; He P; Zhou C; Jing L; Dong B; Chen S; Zhang N; Liu Y; Miao J; Wang Z; Li Q
    J Immunother; 2015; 38(9):350-6. PubMed ID: 26448579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
    Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
    Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific agents target endogenous murine T cells against human tumor xenografts.
    Rund LA; Cho BK; Manning TC; Holler PD; Roy EJ; Kranz DM
    Int J Cancer; 1999 Sep; 83(1):141-9. PubMed ID: 10449621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
    Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
    Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
    Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
    Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GingisKHAN™ protease cleavage allows a high-throughput antibody to Fab conversion enabling direct functional assessment during lead identification of human monoclonal and bispecific IgG1 antibodies.
    Moelleken J; Endesfelder M; Gassner C; Lingke S; Tomaschek S; Tyshchuk O; Lorenz S; Reiff U; Mølhøj M
    MAbs; 2017 Oct; 9(7):1076-1087. PubMed ID: 28805498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.